E

    Elanco Animal Health (ELAN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $23.91
    -0.20 (-0.81%)

    Market Cap: $12.04B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    91%(29/32)
    Avg Surprise
    +26.58%
    Streak
    6 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.21
    Range$0.19 - $0.24
    13 analysts
    EPS Revisions
    7
    0
    7d
    7
    2
    30d
    EPS Estimate Drift
    90d ago$0.20-5.1%
    60d ago$0.19-5.7%
    30d ago$0.19-5.6%
    7d ago$0.20-1.8%
    Current$0.21
    Revenue Consensus
    $1.2B
    Range$1.2B - $1.2B
    11 analysts
    Dec 31, 2026
    EPS Consensus$0.31
    Range$0.28 - $0.40
    15 analysts
    Revenue Consensus
    $1.3B
    Range$1.3B - $1.3B
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.31---
    Sep 26EST
    		-$0.21---
    Jun 26
    		$0.34$0.27+25.93%Beat+30.8%
    Mar 26
    		$0.40$0.34+17.65%Beat+8.1%
    Dec 25
    		$0.13$0.11+14.54%Beat-7.1%
    Sep 25
    		$0.19$0.13+46.15%Beat+46.2%
    Jun 25
    		$0.26$0.20+30.00%Beat-13.3%
    Mar 25
    		$0.37$0.30+23.33%Beat+8.8%
    Dec 24
    		$0.14$0.15-5.79%Miss+75.0%
    Sep 24
    		$0.13$0.12+8.33%Beat-27.8%
    Jun 24
    		$0.30$0.24+25.00%Beat+66.7%
    Mar 24
    		$0.34$0.27+25.93%Beat-24.4%
    Dec 23
    		$0.08$0.11-27.27%Miss-57.9%
    Sep 23
    		$0.18$0.12+50.00%Beat-10.0%
    Jun 23
    		$0.18$0.05+260.00%Beat-50.0%
    Mar 23
    		$0.45$0.29+55.17%Beat+25.0%
    Dec 22
    		$0.19$0.13+46.15%Beat-9.5%
    Sep 22
    		$0.20$0.16+25.00%Beat+5.3%
    Jun 22
    		$0.36$0.25+44.00%Beat+28.6%
    Mar 22
    		$0.36$0.35+2.86%Beat-2.7%
    Dec 21
    		$0.21$0.17+23.53%Beat+75.0%
    Sep 21
    		$0.19$0.17+11.76%Beat+46.2%
    Jun 21
    		$0.28$0.26+7.69%Beat+211.1%
    Mar 21
    		$0.37$0.23+60.87%Beat+184.6%
    Dec 20
    		$0.12$0.09+33.33%Beat-47.8%
    Sep 20
    		$0.13$0.12+8.33%Beat-56.7%
    Jun 20
    		$0.09$0.07+28.57%Beat-67.9%
    Mar 20
    		$0.13$0.24-45.83%Miss-48.0%
    Dec 19
    		$0.23$0.23+0.00%Beat-20.7%
    Sep 19
    		$0.30$0.26+15.38%Beat+3.4%
    Jun 19
    		$0.28$0.26+7.69%Beat+128.9%
    Mar 19
    		$0.25$0.23+8.70%Beat-
    Dec 18
    		$0.29$0.27+7.41%Beat-
    Sep 18
    		$0.29$0.25+16.00%Beat-
    Jun 18
    		$-0.97$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio22.56EV/EBITDA20.16x
    Price/FCF31.52xFCF Yield3.17%
    Profitability
    Profit Margin-3.96%Operating Margin8.63%
    ROE-2.98%ROIC0.78%
    Financial Health
    Debt/Equity0.59xInterest Coverage0.33x
    Current Ratio2.05xQuick Ratio1.10x
    Trading Statistics
    Beta1.69Avg Volume8.20M
    52-Week High$27.9852-Week Low$17.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.28
    SMA 20$23.89
    SMA 50$24.59
    SMA 200$23.68
    EMA 10$24.21
    EMA 20$24.23
    EMA 50$24.27
    EMA 200$22.86

    MACD

    Line: -0.07Signal: -0.15Hist: 0.08

    ADX

    ADX: 10.4+DI: 24.9-DI: 28.7

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down40.0
    PSAR$21.64

    Bollinger Bands

    Upper Band$26.17
    Lower Band$21.61
    %B Position1911%(Upper)
    Band Width0.51

    RSI (14-Day)

    Neutral
    47.2

    Momentum Oscillators

    Stoch %K67.1
    Stoch %D77.5
    Williams %R-40.8
    ROC (10d)1.3%
    Momentum0.30
    CCI (20d)-10.6
    MFI (14d)62.7

    Volatility Measures

    ATR (14d)$0.90(3.8%)
    StdDev (20d)1.14
    Hist Vol55.1%(High)

    Volume Flow

    VWAP$23.78
    OBV85.4M
    AD Line47.6M
    CMF (20d)-0.062

    Volume Metrics

    Avg Vol (20d)8.3M
    Vol Ratio0.6x
    VWMA (20d)$23.64

    Pivot Points

    R3$25.34
    R2$25.05
    R1$24.58
    Pivot Point$24.29
    S1$23.82
    S2$23.52
    S3$23.05

    Advanced Oscillators

    TSI-2.07
    Ultimate Osc54.0
    KST-37.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.37B$1.37B$1.14B$1.14B$1.24B$1.19B$1.02B$1.03B$1.18B$1.21B$1.03B$1.07B
    Cost of Revenue$570.00M$586.00M$555.00M$530.00M$528.00M$509.00M$501.00M$492.00M$495.00M$515.00M$516.00M$487.00M
    Gross Profit$798.00M$785.00M$589.00M$607.00M$713.00M$684.00M$519.00M$538.00M$689.00M$690.00M$519.00M$581.00M
    Operating Expenses$683.00M$641.00M$791.00M$605.00M$629.00M$572.00M$533.00M$561.00M$656.00M$603.00M$597.00M$1.60B
    R&D$92.00M$97.00M$93.00M$89.00M$92.00M$94.00M$81.00M$87.00M$89.00M$87.00M$79.00M$86.00M
    SG&A$449.00M$381.00M$338.00M$351.00M$400.00M$341.00M$300.00M$323.00M$354.00M$337.00M$292.00M$313.00M
    Operating Income$115.00M$144.00M$-202,000,000$2.00M$84.00M$112.00M$-14,000,000$-23,000,000$33.00M$87.00M$-78,000,000$-1,016,000,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$59.00M$57.00M$80.00M$52.00M$48.00M$40.00M$46.00M$58.00M$65.00M$66.00M$67.00M$72.00M
    Income Before Tax$56.00M$87.00M$-259,000,000$-50,000,000$25.00M$60.00M$-51,000,000$559.00M$-32,000,000$12.00M$-127,000,000$-1,097,000,000
    Income Tax Expense$2.00M$30.00M$17.00M$-16,000,000$14.00M$-7,000,000$-43,000,000$195.00M$18.00M$-20,000,000$14.00M$-1,000,000
    Net Income$54.00M$57.00M$-276,000,000$-34,000,000$11.00M$67.00M$-8,000,000$364.00M$-50,000,000$32.00M$-141,000,000$-1,096,000,000
    EBITDA$286.00M$316.00M$-5,000,000$178.00M$242.00M$261.00M$150.00M$787.00M$195.00M$244.00M$93.00M$-852,000,000
    EBIT$115.00M$144.00M$-179,000,000$2.00M$73.00M$100.00M$-14,000,000$617.00M$33.00M$78.00M$-78,000,000$-1,025,000,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ELAN

    News

    Elanco (NYSE: ELAN) reports new insider share trade

    Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc (NYSE: ELAN), reported an insider share transaction involving 117.9362 deferred stock units at a price of $23.97, totaling approximately $3K. These units represent the right to receive common stock or cash equivalent upon termination of employment or a specified future year, as per the Executive Deferral and Stock Match Plan. Following this transaction, Simmons beneficially owns 25,130.1237 deferred stock units.

    Stock Titan•8/26/26•
    Neutral

    Elanco Animal Health CEO Jeffrey N. Simmons Acquires 117.94 Deferred Stock Units

    Jeffrey N. Simmons, CEO of Elanco Animal Health Inc., acquired 117.9362 deferred stock units (DSUs) at $23.97 each on August 21, 2026, as reported in an SEC filing. This transaction increases his direct holdings to 25,130.1237 DSUs. These units, which can be converted to common stock or cash, are part of the company's Executive Deferral and Stock Match Plan.

    Kalkine Media•8/25/26•
    Neutral

    Elanco (NYSE: ELAN) EVP now holds 9,770 deferred units

    Elanco Animal Health Inc's Executive Vice President, Rajeev A. Modi, was granted 61.6158 Deferred Stock Units on August 21, 2026, as part of an award. Each unit represents a share of common stock or its cash equivalent, settling after employment or in a specified future year. Following this grant, Modi's total direct holdings of Deferred Stock Units now amount to 9,770.3122 units.

    Stock Titan•8/25/26•
    Neutral

    Elanco Animal Health (ELAN) Stock Analysis: Unlocking a 30% Upside Potential with Strong Buy Ratings

    Elanco Animal Health (ELAN) is a drug manufacturer for specialty and generic animal health products with a market capitalization of $11.97 billion. Analysts project a significant upside potential of approximately 30.22% with an average target price of $31.21, and the company has received 16 buy ratings and only one hold rating. Despite negative EPS and return on equity, Elanco boasts robust free cash flow and a forward P/E of 18.83, indicating investor confidence in its future earnings potential and strategic growth in the animal health sector.

    DirectorsTalk Interviews•8/24/26•
    Bullish

    Elanco director Kurzius buys $935,920 in company stock

    Elanco Animal Health Inc. director Lawrence Erik Kurzius purchased 40,000 shares of company stock for approximately $935,920. This insider buy follows positive company news including strong Q2 2026 earnings, an upgrade by Fitch Ratings, and a reiterated Buy rating from Stifel, despite some analysis suggesting the stock might be overvalued.

    Investing.com•8/22/26•
    Bullish

    Frequently Asked Questions About ELAN

    Does ELAN pay dividends?
    Elanco Animal Health (ELAN) does not currently pay a regular dividend.
    What is ELAN's P/E ratio?
    Elanco Animal Health has a price-to-earnings (P/E) ratio of 22.56.
    What is ELAN's market cap?
    Elanco Animal Health (ELAN) has a market capitalization of $12.04B with a current stock price of $23.91.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In